NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade GliomasWESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and life-threatening condition affecting children and adolescents.
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer TreatmentsWESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc’s clinical trial capabilities in India, facilitating the advancement of its development-stage neuro-oncology treatment.
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of DirectorsDr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team
NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of DirectorsDr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024NeOnc’s Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug CandidateWESTLAKE VILLAGE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has begun patient enrollment for the Phase 2 clinical trial of NEO100-02™, the company’s first of two drug candidates proceeding through four concurrent clinical trials for various indications and patient populations.
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain TumorsWESTLAKE VILLAGE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has begun enrollment of patients for Cohort 3 out of 6 of the Phase 1 clinical trial of NEO212™, the company’s patented novel hybrid drug designed to deliver a ‘double punch’ against primary and secondary malignant brain tumors.
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 MutationWESTLAKE VILLAGE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, received FDA approval to expand its ongoing NEO100-01™ Phase 2a clinical trial to include Recurrent Grade III Astrocytoma with Isocitrate Dehydrogenase 1 (IDH1) mutation.
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track StatusWESTLAKE VILLAGE, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has completed a $18.5 million financing to support the ongoing development and Phase I and II clinical studies of its novel drug and delivery methods designed to address the persistent challenges with overcoming the blood-brain barrier.
NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement AwardClinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award
NeOnc Technologies Holdings Receives FDA Authorization to Proceed with Phase 1/2 Trials of NEO212 for Primary Brain Tumors and for Brain Metastasis in Combination with Standard of Care TherapyLOS ANGELES, June 27, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company (the “Company,” “NeOnc”), has received authorization by the U.S. Food and Drug Administration (FDA) for the Phase 1/2 clinical study of NEO212, the Company’s drug conjugate therapeutic under development. NEO212 is designed to more efficiently deliver a DNA alkylating agent to the brain for treatment of primary brain tumors and for brain metastases that arise from other cancers.
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory BoardLOS ANGELES, April 18, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory board as a strategic advisor.
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD, Ph.D., has received the Best in Medicine Award by the American Health Council (AHC).
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®LOS ANGELES and CHICAGO and LONDON, March 06, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has expanded its engagement of Anova Enterprises to pursue a pediatric indication for NEO100, an enhanced method of delivering pharma-based therapeutics to the brain designed for the treatment of brain and central nervous system (CNS) diseases.
